Volume 54, Issue 6, Pages (January 1998)

Slides:



Advertisements
Similar presentations
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Advertisements

Volume 57, Issue 5, Pages (May 2000)
Volume 65, Issue 2, Pages (February 2004)
Persistent secondary hyperparathyroidism after renal transplantation
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Beta blockers in the management of chronic kidney disease
Intensive hemodialysis—keeping the faith
Volume 73, Issue 1, Pages 3-5 (January 2008)
Anemia management in chronic kidney disease
Volume 75, Issue 3, Pages (February 2009)
Vitamin D deficiency and heart disease
Volume 57, Issue 5, Pages (May 2000)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Intensive hemodialysis—keeping the faith
Volume 80, Issue 10, Pages (November 2011)
Volume 79, Pages S24-S27 (April 2011)
Volume 54, Issue 2, Pages (August 1998)
Volume 76, Pages S50-S99 (August 2009)
Volume 61, Issue 3, Pages (March 2002)
N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment  Martina Franz, Wolfgang Woloszczuk, Walter.
The need for reliable serum parathyroid hormone measurements
Nephrology Crosswords: Hemodialysis
Use of vitamin D in chronic kidney disease patients
Volume 87, Issue 2, Pages (February 2015)
Chemical and hormonal determinants of vascular calcification in vitro
Gentamicin pharmacokinetics during slow daily home hemodialysis
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Ewa Lewin, Yolanda Almaden, Mariano Rodriguez, Klaus Olgaard 
Volume 80, Issue 5, Pages (September 2011)
Volume 69, Issue 3, Pages (February 2006)
Blood pressure targets in hemodialysis patients
Volume 67, Issue 1, Pages (January 2005)
Persistent secondary hyperparathyroidism after renal transplantation
Changes in the number of circulating TCM and TEM subsets in renal transplantation: relationship with acute rejection and induction therapy  David S. Segundo,
Volume 74, Pages S88-S93 (December 2008)
P. Urena Torres, G. Friedlander, M.C. de Vernejoul, C. Silve, D. Prié 
Volume 56, Issue 2, Pages (August 1999)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Non-immunologic intervention in chronic allograft nephropathy
Volume 87, Issue 3, Pages (March 2015)
Alternate-day dialysis may be needed for hemodialysis patients
Pathogenesis of refractory secondary hyperparathyroidism
Volume 75, Issue 9, Pages (May 2009)
Measurement of renal function in pre-ESRD patients
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients
Volume 80, Issue 3, Pages (August 2011)
Volume 78, Issue 4, Pages (August 2010)
Volume 64, Issue 1, Pages (July 2003)
Fibroblast growth factor 23: the making of a hormone
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients  B. Bammens, P. Evenepoel, H. Keuleers,
Volume 63, Pages S79-S82 (June 2003)
Current status of maintenance hemodialysis in Beijing, China
Volume 63, Issue 2, Pages (February 2003)
Return to dialysis after renal transplantation
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
Volume 60, Issue 6, Pages (December 2001)
Recent developments in the management of secondary hyperparathyroidism
Volume 56, Issue 1, Pages (July 1999)
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Antioxidant therapy in hemodialysis patients: a systematic review
Increased fetuin-A levels following treatment with a vitamin D analog
The ins and outs of phosphate homeostasis
PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.
Marta Christov, Harald Jüppner  Kidney International 
Volume 55, Issue 5, Pages (May 1999)
Volume 83, Issue 1, Pages (January 2013)
Characteristics of sudden death in hemodialysis patients
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Volume 54, Issue 6, Pages 2140-2145 (January 1998) Effect of serum phosphate on parathyroid hormone secretion during hemodialysis  Angel L.M. de Francisco, Maria A. Cobo, Maria A. Setien, Emilio Rodrigo, Gema F. Fresnedo, Maria T. Unzueta, Jose A. Amado, J. Carlos Ruiz, Manuel Arias, Mariano Rodriguez  Kidney International  Volume 54, Issue 6, Pages 2140-2145 (January 1998) DOI: 10.1046/j.1523-1755.1998.00221.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Changes in serum phosphate concentration during the high phosphate hemodialysis (high-P hemodialysis; •) and the phosphate-free hemodialysis (P-free hemodialysis; ○). Values are the mean ± SE, N = 10.*P < 0.05 versus P-free hemodialysis. Kidney International 1998 54, 2140-2145DOI: (10.1046/j.1523-1755.1998.00221.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 The PTH-calcium curve during the high phosphate hemodialysis (high-P hemodialysis; •) and the phosphate-free hemodialysis (P-free hemodialysis; ○). The PTH values at each calcium concentration are the means obtained from the individual PTH-calcium curves obtained in the eight patients studied. *P < 0.05 versus P-free HD. The mean ± SE PTH value at 1.15mM calcium is 767 ± 131 and 554 ± 115 pg/ml for high-P and P-free hemodialysis, respectively (P < 0.05). Note that these values are not identical to the mean basal PTH values presented in Table 2. In Table 2 the mean basal PTH value was obtained from basal PTH values corresponding to each individual basal calcium, which varies from patient to patient. The change from each individual basal calcium concentration to a calcium of 1.15 induces a change in PTH. This explains that the mean PTH at 1.15mM calcium is not the same as the mean basal PTH presented in Table 2. Kidney International 1998 54, 2140-2145DOI: (10.1046/j.1523-1755.1998.00221.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 Individual values of maximal inhibition of PTH secretion (minimal PTH) with hypercalcemia during the high phosphate hemodialysis (high-P hemodialysis) and the phosphate-free hemodialysis (P-free hemodialysis). Dashed circles indicates that P-free hemodialysis was performed first. In all patients the values of minimal PTH were greater during the high-P hemodialysis than the P-free hemodialysis. Kidney International 1998 54, 2140-2145DOI: (10.1046/j.1523-1755.1998.00221.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 2140-2145DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 2140-2145DOI: (10.1046/j.1523-1755.1998.00221.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 2140-2145DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 2140-2145DOI: (10.1046/j.1523-1755.1998.00221.x) Copyright © 1998 International Society of Nephrology Terms and Conditions